Logo

Human Metabolome Technologies Signs Biomarker Deal with Mitsubishi Pharma

Feb 17, 2005

NEW YORK, Feb. 17 (GenomeWeb News) - Human Metabolome Technologies of Yamagata, Japan, yesterday announced a biomarker research collaboration with Mitsubishi Pharma.

 

Under the terms of the agreement, HMT will search for biomarkers for the early detection of drug-induced phospholipidosis using its metabolomics tools, which include capillary-electrophoresis and mass spectrometry technology for small-molecule separation and detection.

 

Financial details of the agreement were not disclosed.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.